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 The major technological hurdle for preimplantation genetic diagnosis 
(PGD) is the inability to provide sufficient quantity and quality of DNA from single 
blastomeres. Therefore, much effort has been invested  in developing methods to 
provide sufficient quantity of DNA for downstream molecular analyses. The whole 
genome amplification (WGA) is one approach designed to overcome these 
problems. This technique would amplify all of the genetic material present in a 
sample containing low amounts of DNA such as that present in a single cell. The 
product of WGA method should be amenable for use in polymerase chain 
reaction (PCR), Real-time PCR (RT-PCR) and comparative genomic 
hybridization (CGH) - based genetic analysis of single cell samples, such as 
blastomeres, and for testing of aneuploidy, single gene defects and sex 
selection.  
 
The objective of this study was to apply WGA and PCR techniques to sex 
determination of preimplantation human embryos (that were created by 
intracytoplasmic sperm injection "ICSI") for the first time in Gaza Strip. In this 
study, parts of SRY (Sex-Determining Region on Y chromosome) and glucose-6- 
phosphate dehydrogenase (G6PD) genes were amplified in 30 donated  surplus 
embryos by PCR techniques.  
 
This study proved that WGA using the REPLI-g Mini Kit (Qiagen, USA) is 
applicable for very low amounts of DNA and this would open the door to 
diagnose several inherited diseases by genetic analysis to prevent couples who 
have risk for passing an inherited disease to offspring from giving birth to affected 
offspring. Sex determination by PCR is a fast and convenient technique, 
requiring only one PCR reaction, with the products being easily visualized on an 
agarose gel and it is useful for examining the sex of embryos prior to transfer to 
mother′s uterus.  
 
Key Words: Polymerase Chain Reaction (PCR), Whole Genome Amplification 
(WGA), blastomere, Sex  determination. 
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من خمية جنين ناتج من عممية التمقيح Y   وXمي  والبحث عن منطقتين محددتين عمى كرموز
 PCRالمجهري باستخدام تقنية 
 ممخص الدراسة
إن كمية المادة الوراثية القميمة في الخمية الواحدة من الجنين الناتج من التمقيح المجهري هي العائق األساسي 
لحصول عمى كمية لأمام تشخيص األجنة قبل إرجاعها إلى رحم األم، لذلك استمرت الجهود من أجل تطوير التقنيات 
الجينوم الكامل لممادة إكثار فتم التوصل إلى تقنية . كافية وجيدة من المادة الوراثية الستخدامها في الفحوصات الوراثية
ن كانت من خمية واحدة، قميمة جدًا من المادة الوراثيةالوراثية في العينات التي تحتوي عمى كمي  مما يمكننا من ة وا 
  التي تستخدم لتشخيص األجنة قبل إرجاعها لمرحم مثل تقنية البيولوجيا الجزيئيةتطبيق العديد من تقنيات
Polymerase Chain Reaction (PCR), Real-Time PCR (RT-PCR), Comparative 
Genomic  Hybridization (CGH) ، وبالتالي يتم تشخيص الخمل في عدد الكرموزومات واألمراض ذات
 . الخمل الجيني الواحد وتحديد جنس األجنة
 الستخدامها في تحديد Blastomereمن هنا كان الهدف لهذه الدراسة تطبيق آلية إكثار الجينوم من خمية 
فقد تم استخدام . جنس األجنة الناتجة من التمقيح المجهري قبل إرجاعها إلى رحم األم وذلك ألول مرة في قطاع غزة
 عمى SRY gene وذلك من خالل البحث عن –من األجنة الفائضة -  جنين 30 لتحديد جنس PCRتقنية 
. X  عمى كروموزوم G6PD geneو  Yكرموزوم 
 
حتى عمى مستوى الخمية الواحدة مما سيفتح  Kit  REPLI-gأثبتت الدراسة فاعمية إكثار الجينوم باستخدام
. الباب أمام تشخيص العديد من األمراض الوراثية لتجنيب العائالت التي لها تاريخ مرضي إنجاب أطفال مصابين
  لتحديد الجنس سريعة وسهمة وناجحة لتحديد جنس األجنة قبل إرجاعها إلى رحم PCRكما اثبتت الدراسة أن تقنية 
 .  األم
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                                         Introduction  
1.1. Overview: 
Preimplantation genetic diagnosis (PGD) is a technique that can be used in 
conjunction with in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) 
to screen embryo(s) for sex, chromosomal abnormalities and specific genetic 
disorders prior to transfer to the uterus [1] . 
PGD was first employed in 1989 with the subsequent birth of normal 
females to couples at risk of various X-linked recessive diseases and, in 1990 for 
autosomal recessive diseases. More than 2,000 children have now been born 
following these procedures demonstrating that embryo biopsy and PGD can be 
safely performed in humans. Handyside et al. (1989; 1990) were the early pioneers 
in diagnosis of genetic diseases in human preimplantation embryos. Since then, 
PGD has been practiced widely throughout the world  [2-4]. 
Throughout the 1990‟s, the use of PGD was limited to screening for a 
handful of severe, irreversible, genetic conditions, including sickle-cell anemia, Tay 
Sachs disease, Duchenne‟s muscular dystrophy, and Beta-thalassemia. 
Consequently, PGD was used for the screening of embryos for common 
aneuploidies in couples undergoing IVF procedures for infertility with a history of 
recurrent pregnancy loss, repeated IVF failures and advanced maternal age 
(women age 35 and older). Moreover, couples who do not meet the classic 
definition of infertility but are considered at risk for passing on a single gene 
disease to offspring may employ IVF techniques to allow for PGD, so that affected 
embryos can be deselected. In this situation, the IVF procedures are being 
performed solely to accomplish PGD. Thus, PGD is becoming valuable for the 
detection of sporadic chromosomal abnormalities with the goal of increasing 
reproductive success (as well as prevention of the birth of affected offspring). In 
this context, PGD is a screening procedure to detect those aneuploidies most 
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commonly observed after birth or in miscarriages (involving detection of 
chromosomes 13, 18, 21, X, and Y). Together these chromosomes account for 
about 95% of all chromosomal abnormalities [3].   
PGD involves removing a single cell from a 3-day old IVF embryo 
(containing from 6 to 8 cells or a blastocyst) by  a process called blastomere biopsy 
and then analyzing that cell for specific genetic or chromosomal abnormalities [3]. 
The patients that come forward for PGD are fertile and infertile. PGD is 
recommended most frequently for patients with unexplained infertility, recurrent 
miscarriages, unsuccessful IVF cycles, advanced maternal age, or male factor 
infertility. Additionally, PGD can be used for detecting at-risk couples who have 
already had a child with a genetic defect or whose family has a history of specific 
inherited disorders such as single gene defects and chromosomal abnormalities. 
The purpose of PGD is to improve the chance of conception for patients with 
genetic abnormalities, and to make it likely that their offspring will not suffer from 
the genetic defect carried by the family. In so doing, one avoids the moral or ethical 
dilemmas which arise from the termination of the pregnancy once it has begun [2].  
In response to the development of PGD, several countries passed laws to 
limit its use. Motivations to establish a process to consider the full ethical, legal, 
and social implications of this emerging technology, to ban it outright, or restrict its 
applications, centered around a common recognition of the eugenic nature of PGD. 
Some countries, including Germany, Austria, Ireland, Switzerland, and Western 
Australia, outright banned the procedure for any use. Others, such as the United 
Kingdom, France, the Netherlands, Belgium, Italy, and Greece, chose to limit the 
use of PGD to a narrow range of applications, and in some cases, such as the 
United Kingdom, establish a process for considering future applications of the 
technology [3]. 
In the United States (U.S), however, no such law or regulatory process has 
been enacted to limit the use of PGD. Instead, a virtually unregulated fertility 
industry has been left to offer any and all available PGD applications to its clients. 
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As a result, more than 2/3 of the 50 or so fertility clinics worldwide offering PGD are 
in the U.S. In addition, uses of PGD in the U.S. have gone well beyond selecting 
against “severe” diseases that tend to strike early in childhood. These include the 
use of PGD for non-medical sex selection; avoidance of late-onset diseases, such 
as Alzheimer‟s; and use of PGD solely for selection of a child to serve as a tissue-
match for another. None of these new applications were subject to formal 
regulatory review or public deliberation prior to their use [3].  
It has been estimated that PGD can currently be used to select against 100 
different genetic conditions, and that as many as 2,000 children have been born, 
worldwide from the procedure. The growth of PGD can only be expected to 
accelerate in the foreseeable future as the march continues to associate single 
genetic mutations with diseases [3]. 
Over the course of human history, the gender of a newborn child has mostly 
been a surprise and an uncontrollable aspect of the lifecycle. Technology today 
allows for parents to not only know the gender of their child before birth, but to 
choose the child’s gender before being implanted in the womb. Advancements in 
reproductive technologies over the past few decades have given parents the 
freedom and ability to control many aspects of bearing children. IVF and testing 
embryos for abnormalities are not new in the developed nations of the world, but 
using these technologies to select gender is a recent and controversial movement 
for reproductive freedom [3, 5]. 
In general, sex-selection may be performed at three different levels (pre-
conception, PGD and post-implantation). The two levels, pre-conception and post-
implantation, will not be covered in this manuscript. The PGD is the scope for this 
study. Broadly, the reasons people have for wanting to select the sex of offspring 
fall into two categories: medical and non-medical [6]. 
 
Polymerase chain reaction (PCR) and fluorescence in situ hybridization 
(FISH) are the two most commonly used methods in PGD in many IVF/ICSI 
laboratories. Most researches in PGD are focused on new methods of single cell 
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analysis to reduce the disadvantages of conventional PCR. The more novel and 
the most successful approaches for global genome screening of single cells are 
comparative genomic hybridization (CGH) and single nucleotide polymorphism 
(SNP) analyses. In this study we employed a PCR assay for the simultaneous 
detection of X and Y chromosomes on human blastomeres. In PCR, both X- and Y-
specific fragments are amplified with primers which are common to both 
chromosomes, fragments specific to each chromosome are generated: both an X 
and a Y fragment in male embryos and, due to the absence of a Y chromosome, 
only an X-specific fragment is produced in females. The efficiency and accuracy of 
this assay are high; it generates no false positive amplification signals. We 
therefore believe that it is suitable for gender determination in preimplantation 
diagnosis for couples at risk for X-linked genetic diseases and for non-medical sex 
selection purposes [2, 7] . 
Whole genome amplification (WGA) is a technique that amplifies the entire 
genome from a single cell up to microgram levels. Sufficient DNA can be amplified, 
allowing diagnosis of any known single gene defect that would have been 
impossible otherwise, and multiple tasks which need abundant DNA can be 
performed from WGA products. Moreover, the WGA products can be analyzed as 
a template for multi-loci, multi-gene, and genome research during the subsequent 
DNA analysis. WGA relies on degenerate oligonucleotide primed-PCR (DOP-PCR) 
and was first described by Telenius et al. (1992). The starting template DNA of 
DOP-PCR can be as little as 15 pg, and the quantity of DNA product is sufficient 
for many downstream processes [2].  
In recent years, Gaza has witnessed a remarkable increase in the number 
of Infertility and IVF centers, but this increase must be accompanied with 
appropriate technical services to improve the rate of pregnancy success and help 
couples suffering from infertility and genetic diseases. As such, PGD would be the 
most useful and advanced technique. The use of PGD will serve the couples with 
chromosomal abnormalities, single gene diseases and non-medical sex selection. 
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In this study, we applied a WGA technique and used Y- and X-specific PCR 
on the DNA amplified from one or two blastomeres from embryos that were 
donated for research. 
1.2. Significance: 
Optimizing a technique that enables analysis of DNA extracted from single 
blastomeres is valuable for PGD in all of the following situations: 
 
 Reducing birth of affected children with genetic diseases. 
 Couples who have many children of one gender may need to select the 
other gender. 
1.3. Overall objective: 
The overall objective of the study is to optimize whole genome amplification 
and PCR on DNA extracted from single blastomeres.  
1.4. Specific objectives of the study: 
 
 Employing WGA technique for amplifying whole genomic DNA of single 
blastomeres.  
 Applying sex determination on single blastomeres for the first time in Gaza 
Strip by PCR. 
 Performing the blastomere biopsy by acid Tyrode's.   












2.1. Infertility and Assisted Reproductive Techniques (ARTs) 
Infertility is defined as the failure to achieve a successful pregnancy after 12 
months or more of regular unprotected intercourse. It is commonly accepted that 
infertility affects 15 to 20% of couples. The causes of infertility can be divided into 
four major categories: 1) the female factor 35%; 2) the male factor 30%;                  
3) combined factors 20 %; and 4) unexplained infertility 15% [8]. 
 
ART is a group of different methods used to help infertile couples. It involves 
handling eggs, sperm, or both outside the human body. It constitutes a very 
valuable tool in the infertility treatment in addition to pharmacological and surgical 
methods. So that, ART is becoming an international panacea for couples struggling 
with infertility. The increasing popularity of these techniques and the data 
generated have given us a better understanding of the efficacy, consequences and 
costs of these procedures. There still remain many unanswered questions and 
controversies surrounding the use of IVF and ICSI. Increased experience, better 
refinement of these techniques and clearer indications for IVF and ICSI will 
inevitably minimize the risks associated with this procedure  
 
Since 1978, the field of ARTs has witnessed spectacular scientific advances 
and additional medical applications and  since that same year, nearly one million 
babies have been born worldwide as the result of ARTs. It has been estimated that 
in some European countries up to 5 % of all births are now due to ART. The 
potential of ART is now not limited to infertile couples. It can help fertile couples as 
well to conceive healthy children through the application of the new technologies of 
PGD and embryo selection [9]. 
The common methods of ART include: IVF, ICSI and intrauterine  
insemination (IUI).  
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2.1.1. In Vitro Fertilization )IVF( 
 
IVF means fertilization outside of the body. IVF is the old traditional way. It was 
used when a woman's fallopian tubes are blocked or when a man produces normal 
sperm. Specialists treat the woman with a drug that causes the ovaries to produce 
multiple eggs. Once mature, the eggs are removed from the woman. They are put 
in a dish in the lab along with the man's sperm for fertilization. After 3 to 5 days, 
healthy embryos are implanted in the woman's uterus [10]. 
 
2.1.2. Intracytoplasmic Sperm Injection )ICSI( 
 
ICSI is a microscopic procedure used to facilitate fertilization by injecting a 
single sperm directly into the oocyte (Figure 2.1). ICSI is often used for couples in 
whom there are serious problems with the sperm. Sometimes it is also used for 
older couples or for those with unsuccessful IVF attempts. ICSI has become a 
routine and widely accepted treatment for infertility [10, 11]. 
 
 Figure 2.1. A single sperm is injected directly into an egg [12]. 
 
2.1.2.1. Early human embryo development in vitro: 
The oocytes are collected by transvaginal ultrasound guided aspiration of the 
follicular fluid. Then oocytes are transferred to suitable culture medium and 
fertilized by IVF or ICSI, whereby a single sperm penetrates a mature oocyte. On 
day 1 after oocyte retrieval, oocytes are examined for the presence of two 
pronuclei (2 PN) that indicate normal fertilization. These oocytes are separated 
from the failed or abnormally fertilized oocytes and are returned to culture for 
further development. The fertilized egg undergoes mitotic cell division and reaches 
the eight-cell stage around 3 days post-fertilization (Figure 2.2). Morula formation is 













Figure 2.2. Early human embryo development in vitro. a. pronuclear stage embryo,  
b-e. 2 -10 cells embryo, f. morula, g. blastocyst (the arrow points to inner cell mass), h. blastocyst 




2.1.3. Intrauterine Insemination )IUI( 
IUI  that is often called artificial insemination. In this procedure, the woman 
is injected with specially prepared sperm. Sometimes the woman is also treated 
with medicines that stimulate ovulation before IUI. IUI is often used to treat: mild 
male factor infertility, women who have problems with their cervical mucus and 
couples with unexplained infertility [10]. 
2.2. Preimplantation Genetic Diagnosis )PGD( 
PGD is currently one of the practical options available for couples at-risk to 
avoid the birth of children with genetic and chromosomal disorders. Despite its 
novelty, PGD has already become an alternative to traditional prenatal diagnosis, 
allowing establishing only unaffected pregnancies avoiding the risk for pregnancy 
termination. PGD is presently an excellent option for preventing various genetic 
disorders, and appears to be of special value for avoiding age-related aneuploidies 
in patients of advanced reproductive age. PGD has  been accepted in most parts 




by the present time, which have resulted in birth of more than 1,000 healthy 
children [13]. 
PGD has been recommended and carried out for the following indications: 
advanced maternal age, repeated ICSI failure, repeated early spontaneous 
abortion,  abnormal gamete cell morphology and for couples who have children 
suffering from certain genetic diseases [14]. 
2.2.1. Sources of genetic material for PGD 
There are potentially three types of cells suitable for PGD analysis including 
polar bodies (PBs) from the oocyte/zygote stage, blastomeres from cleavage stage 
embryos, and trophectoderm cells from blastocysts. The most commonly used 
method for performing PGD involves testing blastomeres during the cleavage 
stage.  The expertise of an embryologist is fundamental to ensure successful 
biopsy while maintaining embryo viability. The first stage of any biopsy procedure 
is to make a hole in the zona pellucida that surrounds the oocyte or embryo. Acid 
Tyrodeʼs drilling was the first method used. The most recent development is the 
use of a laser for zona drilling, potentially the most precise and safest  method [15]. 
 
2.2.1.1. PB biopsy 
 
A mature oocyte is characterized by the presence of a first PB (Figure 2.3), 
that  contains a complement of 23 bivalent maternal chromosomes. This discrete 
structure can be removed and used for genetic testing or for aneuploidy screening 













After fertilization, a second PB (Figure 2.4) containing a complement of 23 
maternal chromatids, is extruded from the oocyte and can also be tested to provide 





Figure 2.4. Second PB biopsy [16]. 
 
Since over 90% of chromosomal errors originate from maternal meiosis, the 
PB approach is of special value for PGD of age-related aneuploidies and various x-
linked recessive disorders, where the PB provides information only about the 
maternal contribution to the embryo. To obtain the PB the oocyte is held by the 
holding pipette with the PB at the 6 or 12 o'clock position. A slit is drilled 
mechanically in the zona pellucida and the PB is aspirated with a thin, polished 
glass needle. The oocyte is then inseminated using the ICSI technique, by 
introducing the injection needle through the breach already opened in the zona. 
The whole procedure does not  adversely affect either fertilization or cleavage 
rates [13, 16]. 
 
2.2.1.2. Blastomere Biopsy  
On the third day post-insemination, the fertilized embryos are usually six to 
eight cells. These cells are called blastomeres. The biopsy procedure requires an 
opening in the zona pellucida ~ 20 μm in diameter which is performed chemically, 
mechanically or using contact laser. The location of the embryo is adjusted in order 
to have a nucleated blastomere at the 3 'clock position (Figure 2.5). The 
blastomere is then slowly aspirated and gently released into the medium. After 
biopsy is taken, the embryo is placed in fresh culture medium and incubated until 




Figure 2.5. Blastomere biopsy [17]. 
Palmer et al. (2002) evaluated a strategy involving embryo biopsy on day 3 
post-insemination, following culture in blastocyst sequential media, transfer of 
unaffected embryos was done on day 5 post-insemination. ICSI cycles were 
initiated in 15 couples at risk of transmitting β-thalassaemia major. Oocyte retrieval 
and ICSI were performed according to standard protocols. Embryo culture 
consisted of blastocyst sequential media. Embryos were biopsied on day 3 post-
insemination using acid Tyrode‟s for zona drilling, and the single blastomeres were 
genotyped by a protocol involving nested PCR and denaturing gradient gel 
electrophoresis analysis. Forty of 109 (37%) embryos biopsied on day 3 post-
insemination developed to blastocysts by day 5 post-insemination, with at least one 
blastocyst available for transfer in 12 cycles (80%). Genotype analysis 
characterized 51/109 (47%) embryos as unaffected for β-thalassaemia major, of 
which 28 reached the blastocyst stage. Transfer of 37 day 5 post-insemination 
embryos (blastocysts and non blastocysts) initiated 8 clinical pregnancies. 
Implantation rate per embryo transferred was 12/37 (32%). Embryo biopsy on day 
3, followed by delayed transfer until day 5 post-insemination offers a novel and 
effective strategy to overcome the time limit encountered when performing PGD, 
without compromising embryo implantation [18]. 
2.2.1.3. Blastocyst Biopsy 
On the fifth day post-insemination  blastocyst is formed (Figure 2.6), that 
have hundreds of cells that have differentiated into an inner cell mass (that will 
become the fetus) and the trophectoderm (that will become the placenta).  During 
blastocyst biopsy, a hole is made in the shell of the embryo and several cells are 
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removed from the trophectoderm.  The advantages of blastocyst biopsy are that 
more cells are sampled for a more accurate diagnosis.  It is thought to be less 
stressful to the embryo compared to day 3 embryo biopsy, in which 1/6 to 1/8 of 
the embryo is removed.  In addition, it is now possible to test blastocysts on day 5 
and transfer the chromosomally normal ones back to the womb the following day.  




Figure 2.6 Blastocyst biopsy [19]. 
McArthur et al. (2005) compared multiple-cell trophectoderm biopsy for PGD 
from day-5 blastocysts. PGD patients aged > 44 years with at least one IVF 
blastocyst  suitable for biopsy were recruited from January 2002 through August 
2004. Biopsy of trophectoderm from blastocysts on day 5 or 6 were used on the 
same day PGD for mutation testing, translocation testing, aneuploidy screening or 
sex selection. Spare, normal biopsied blastocysts were cryostored for possible 
later transfer. In 231 started PGD treatment cycles, unambiguous results were 
obtained from 974 of 1,050 biopsied blastocysts (93%); all blastocysts survived the 
biopsy procedure by reconstitution of their blastocele. One hundred nineteen 
women (median age, 36 years) have had 127 blastocysts transferred fresh (fetal 
heart–positive implantation rate, 41%). Of 146 blastocysts cryostored, 27 have 
been thawed (all with > 50% cell survival) and 24 were transferred (implantation 
rate, 26%). Fifty three pregnancies have been delivered or were ongoing by the 
time of reporting, with an additional 4 clinical miscarriages (7%) and 6 subclinical 
miscarriages (total miscarriage rate, including biochemical pregnancies, 16%). 
There were no twin pregnancies. With technically appropriate blastocyst culture 
and freezing, blastocyst biopsy and cryostorage and later transfer of biopsied 
blastocysts is shown to be a practical and probably preferable path to 
preimplantation genetic testing of embryos compared with cleavage stage embryo 
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biopsy, being accompanied by a high implantation rate (and hence more conducive 
to elective single embryo transfer) and by a low rate of twinning and miscarriage 
[20]. 
The authors concluded that biopsy and testing of blastocysts is both feasible 
and practical in IVF laboratories that are skilled in low oxygen tension blastocyst 
culture using an effective stage-specific medium, and that this development 
constitutes a substantial advance for PGD practices specifically and for IVF 
practices generally [20]. 
2.2.2. Indications and applications for PGD 
    2.2.2.1. PGD for aneuploidy screening (PGD-AS) 
A significant proportion of pregnancy wastage is caused by numerical 
chromosome imbalance or aneuploidy. This is evidenced by the observation that > 
50% of first trimester spontaneous abortuses are aneuploid. In a recent study by 
Spandorfer et al., 71% of pregnancy losses with fetal heartbeat were 
chromosomally abnormal. The association between chromosomal disorders and 
age was particularly evident, ranging from 65% in women 39 and younger to 82% 
in women 40 and older. It has been suggested that PGD would reduce this rate of 
loss. In a multicenter study, controls were compared with a test group undergoing 
embryo biopsy and PGD for aneuploidy of chromosomes X, Y, 13, 18, and 21. The 
results revealed significant reduction in spontaneous abortions (measuring 
pregnancy as the presence of a heart beat) from 23% in the controls to 9% in the 
PGD group. In another study, a spontaneous abortion rate of only 9% was reported 
after PGD of aneuploidy for 343 cases in women over 36 years old instead of an 
expected frequency in excess of 16% [21, 22] . 
 
Jobanputra et al.  reported that FISH with probes for chromosomes 13, 15, 
16, 18, 21, 22, X, and Y can detect 83% of the chromosomally abnormal fetuses 
routinely. Using these same probes, PGD should also eliminate close to 80% of all 
chromosomally abnormal embryos at risk of causing a spontaneous abortion [21]. 
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Gianaroli et al. (2003) used fluorescent probes for the simultaneous 
detection of different chromosomes in successive rounds of FISH. In all, 141 
embryos were analyzed for 5 chromosomes (X, Y, 13, 18, 21), 345 for 6 
chromosomes (X, Y, 13, 16, 18, 21), and all the others for (8, 9) chromosomes 
including those implicated in the most frequent aneuploidies detected in 
spontaneous abortions and trisomic pregnancies (X, Y, 13, 15, 16, 18, 21, 22). In 
the case of translocations, the chromosomes involved in the translocation were 
screened using enumerator probes (robertsonian translocations) or a combination 
of centromeric and telomeric probes (reciprocal translocations); embryos resulting 
normal or balanced were also screened for the chromosomes involved in 
conventional aneuploidy analysis. In the same study, 5082 embryos were 
generated from 828 cycles and 4244 of them were selected for embryo biopsy. A 
diagnosis was obtained in 4213 embryos (99%); 1381 had a normal chromosomal 
complement (33%) and made the transfer possible in 552 cycles (67%). An 
average of 1.8 ± 0.7 euploid embryos were replaced yielding 160 clinical 
pregnancies (29%) and an implantation rate of 20.4%. The take-home baby rate 
was 23% [23]. 
Rubio et al. (1999) reported an increased frequency of sex chromosome 
disomies in sperm samples in couples with repeated spontaneous abortion. 
Devillard et al. (2002) reported a high rate of disomy and diploidy in patients with 
severe morphologically abnormal sperm. Kahraman et al. (2004) reported that a 
cumulative pregnancy rate of approximately 30% is encouraging after PGD, 
implying the beneficial effect of elimination against chromosomally abnormal 
embryos. In Staessen (2004), 63 % of the embryos were found to be 
chromosomally abnormal, and therefore not suitable for embryo transfer, and in 
25.7 % of the cycles with PGD all embryos were found to be abnormal, and no 
embryo transfer could be performed [14, 24]. 
The New York University School of Medicine Fertility Center reported on 
their ten-year experience with PGD. Included in the report were all IVF, embryo 
2000. During this time, 304 PGD-IVF cycles were performed on 190 patients; 181 
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(60%) were performed for single gene defects and 123 (40%) were performed for 
chromosomal aneuploidies (AS) and translocations (TS). Implantation rate for 
single gene disorders (SGD), AS, and TS were 24%, 27%, and 47%, respectively. 
Clinical pregnancy rates for SGD, AS and TS were 35%, 37%, and 67%, 
respectively. Eighty-eight patients underwent PGD for AS, 44 for recurrent 
miscarriage, 37 for advanced maternal age (≥ 38 years and all with a history of 
elevated follicle stimulating hormone (FSH)), five for repeated IVF failures, seven 
for couples with an aneuploid fetus/child, and 18 for a combination of the above. 
Miscarriage rates, defined as a proportion of gestational sacs not resulting in live 
births, were 22% for SGD, 29% for AS, and 14% for TS. When calculated as the 
proportion of fetal heartbeats aborted per fetal heartbeats detected, the rates were 
much lower: 12% for SGD, 12.5% for AS, and 14% for TS. The authors 
encouraged genetic counseling and confirmatory chorionic villus sampling (CVS) or 
amniocentesis and concluded that PGD may help improve ongoing pregnancy 
rates in poor-prognosis patients [23]. 
 
Many IVF laboratories perform PGD with FISH to select embryos that are 
free from some  aneuploidies in an attempt to improve implantation, pregnancy and 
live birth rates in particular categories of IVF patients. The usefulness of FISH is 
limited because only  few chromosomes can be detected simultaneously in a single 
biopsied cell. Global genome analysis at the single cell level can now be achieved 
by CGH [22]. 
 
The first successful clinical application of CGH in PGD was for a 38 years 
old woman who had suffered many years of primary infertility and then recurrent 
implantation failure in IVF including some embryos that had been diagnosed as 
normal for five chromosomes using FISH on biopsied blastomeres. CGH analysis 
of biopsied blastomeres found only one of five embryos to be normal for every 
chromosome. This predicted XX embryo was transferred and resulted in the birth 
of a healthy female infant. This patient was included in a series of 20 women with 
implantation failure who had PGD for aneuploidy testing using CGH. Some of 
these women chose to have FISH analysis for chromosomes 13, 16, 18, 21 and 22 
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of  blastomeres from half of their embryos and CGH on the remaining embryos. 
The fetal heart pregnancy rate and implantation rate was higher after transfer of 
embryos diagnosed as normal by CGH compared to FISH but the sample size was 
too small for this difference to be statistically significant. Sixty percent of the 
embryos analysed by CGH had at least one chromosome abnormality. Many 
biopsied blastomeres had multiple abnormalities and 11% had a partial aneuploidy. 
Interestingly at least one aneuploidy of every  chromosome was observed in these 
blastomeres biopsied from just 126 early embryos. Clearly CGH is able to detect 
more chromosome errors than FISH and it was conservatively estimated in this 
study that FISH for five (13, 16, 18, 21, 22) or nine (X, Y, 13, 14, 15, 16, 18, 21, 22) 
chromosomes would have missed the aneuploidies in 38 and 25% of embryos 
respectively and diagnosed them as normal [22]. 
 
So far, more than 2000 cases of PGD of aneuploidy have been performed, 
either using embryo biopsy or PB biopsy. Large numbers are needed to 
demonstrate a decrease in trisomic offspring from the 2.6% trisomies for 
chromosomes 13, 18 or 21 detected in CVS in women 39 years old, to 0.3% after 
PGD [25]. 
 
2.2.2.2. PGD for single gene disorders  
 
Single gene disorders are genetic conditions caused by the alteration or 
mutation of one specific gene in the affected person‟s DNA. Among the serious 
disorders caused by single gene defects are cystic fibrosis, Duchenne muscular 
dystrophy, haemophilia, Huntington's disease, the thalassaemias, sickle cell 
disease, and a number of uncommon hereditary cancers. Although more than 
10,000 single gene disorders have been described, most of them are individually 
rare. It is estimated  that around twenty of these disorders account for 70-80% of 
all the major genetic diseases seen in the UK. The birth prevalence of single gene 
disorders and chromosomal syndromes is about 2% and for all congenital 
malformations it reaches up to 3%. For many affected couples there is a high risk 
that the condition will recur in their children. About 1% of cancers are due to 
specific inherited forms and the techniques of  molecular biology can now be used 
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for diagnosis or predictive testing in families at risk. Of potentially much greater 
impact is the identification of genetic predispositions to common cancers, notably 
breast, ovary, colon and prostate. Up to 10% of these cancers may be determined 
by a single major gene and arise in the context of a strong family history [26]. 
 
The PCR was the first technique developed for the analysis of DNA from 
single cells. Monogenic diseases were also the first genetic abnormalities to be 
diagnosed in embryos. Currently, PGD is available for a large number of 
monogenic disorders, that is, conditions that are due to single gene defects only 
and that usually show typical inheritance patterns (autosomal recessive, autosomal 
dominant or X-linked) or a chromosomal structural aberration (such as a balanced 
translocation). PGD helps couples identify embryos carrying a genetic disease or a 
chromosome abnormality, thus avoiding diseased offspring [27]. 
 Gianaroli et al. (2003) underwent a study on 157/177 (89%) embryos, that 
were generated by 30 cycles, for genetic analysis, 56 were wild type, 40 were 
affected, 59 were healthy carriers of the disorder (cystic fibrosis and thalassemia) 
and two embryos with a normal allele had no result obtained for the second 
mutation investigated. Embryo transfer was possible in 25 cycles and generated 
six clinical pregnancies with an implantation rate of 20.0 %. In all cases, PGD 
results were confirmed by prenatal diagnosis and by the birth of six healthy, 
unaffected infants. Four of the six children were born from carriers of cystic fibrosis 
mutations, and two from carriers of thalassemia mutations. Following the transfer 
of two embryos, one patient with PGD for thalassemia had two gestational sacs 
with three fetal heart beats. The couple decided to undergo selective fetal 
reduction of the monozygotic twins [28]. 
2.2.2.3. PGD for maternal age  
The highest increase in aneuploidy detected at cleavage stage occurs after 
age 39. Recent data indicates that implantation for patients 35–39 also may 
increase after PGD although the difference with controls is still not statistically 
significant. Data from several centers indicate similar implantation for PGD cycles 
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from 36 to 42; decreasing only when there are insufficient normal embryos for 
transfer. Despite the high rate of chromosome abnormalities after age 40, even 
single embryo transfers after PGD have resulted in acceptable implantation and 
pregnancy per transfer (35%) in a group of patients with an average maternal age 
of 42 [25].  
  Gianaroli et al. (2003) applied PGD for aneuploidy in 435 cycles with a 
maternal age ≥36 years and a normal karyotype. A total of 2231 embryos were 
diagnosed resulting in 688 chromosomally normal (31%) whereas the remaining 
1543 (69 %) carried chromosomal abnormalities which were not compatible with a 
healthy implantation. Euploid embryos were replaced in 279 cycles generating 74 
clinical pregnancies (27 %) and an implantation rate of 18.3 %. The take-home 
baby rate was 20 % per patient. The percentage of chromosomally abnormal 
embryos increased proportionally to age, ranging from 63 % in women of 36–37 
years to 81 % in patients aged 43 years and older. Pregnancy and implantation 
rates varied accordingly with a significant decrease starting at 43 years where the 
take-home baby rate per patient was 7 % compared to 30 % in the group 36–37 
years [28]. 
2.2.2.4. PGD for repeated IVF failure 
Repeated IVF failure is usually defined as three or more unsuccessful IVF 
attempts or implantation failure after the replacement of more than 10 embryos. 
However, this classification will select different patients in different IVF centers with 
different pregnancy rates. Several groups have published their results on PGD for 
the indication of repeated IVF failure. According to Gianaroli et al. (1997), 
chromosome abnormalities increased with increasing number of failed cycles, from 
40 % with 2, to 50 % with 3 to 67 % with 5 or more. In another study, they found 
higher rates of chromosome abnormalities (60 %) than in controls in a population 
of patients relatively young an (average maternal age of 32), with the majority of 
the abnormalities not being aneuploidy but mosaicism, polyploidy and haploidy. A 
study by Pehlivan et al. (2002) also found more chromosome abnormalities in 
repeated IVF failure (67 %, average maternal age 36) than in controls (32 %, 
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average maternal age 31.6), but most of the  abnormalities (75 %) were aneuploidy 
and not mosaics. Further differences were found by Gianaroli, because in patients 
with ≥ 2 previous cycles they found only 31 % an (average maternal age 40) 
chromosome abnormalities, similar to the 33.4 % an (average maternal age 40) 
found in controls. The difference in maternal ages, and number of failed cycles in 
these may be the cause of the detected differences in types and frequencies of 
abnormalities [25].  
Because of the high rates of abnormalities detected by several studies in 
repeated IVF failure patients, PGD has been suggested as a mean of improving 
the odds of conceiving in these patients [25]. 
 
2.2.3. Problems with PGD 
2.2.3.1. allele drop out (ADO) 
 
ADO, the random amplification failure of one of the two parental alleles, 
remains the most significant problem in PCR-based PGD testing since it can result 
in serious misdiagnosis for compound heterozygous or autosomal dominant 
conditions. ADO is observed only after PCR amplification from a single cell or a 
small number of cells and randomly affects both alleles. Recent studies have 
shown that the levels of ADO in PCR assays may vary from 0.0% to 60.0%. Allele 
drop out is a well-known phenomenon when performing PCR on single cells. It 
depends on the cell type analyzed, the genes tested, the lysis conditions, as well 
as the PCR conditions. The precise causes of ADO remain unknown but clearly 
both intrinsic and extrinsic factors may be responsible. In blastomeres, some ADO 
can be accounted for by the high levels of chromosomal mosaicism observed in 
human preimplantation embryos, specifically the existence of haploidy which is 
observed in an estimated 7% to 15% of blastomeres. ADO can be ruled out by 
analyzing more than one cell per embryo. In a multiplex reaction, the detection of 
ADO can be virtually eliminated if more than three cells are taken and 
independently analyzed. Although blastocyst biopsy could make this approach 
feasible, at present this would be an unacceptable strategy for cleavage stage 
embryo biopsy and raises issues over whether even biopsy of two cells is 
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acceptable in order to maintain a respectable pregnancy rate. Sermon et al. (1997, 
1998) reported a reduction in ADO from 24% to 6.5% for lymphoblasts and 22% to 
4.9% for blastomeres by using fluorescent PCR. However, other reports indicate 






The accuracy of PGD for aneuploidy is approximately 90%. This means that 
the error rate is 10%. Within this chance of misdiagnosis, there is a false negative 
rate, a false positive rate, the chance for no result and the chance for mosaicism. A 
mosaicism is defined as the embryo having cells with different chromosome or 
genetic make-up. Typically, all cells of the embryo have the same chromosomal 
make-up as they originate from the same fertilized egg. However, it is possible for 
cells of the same embryo to have differing numbers of chromosomes. When the 
cell analyzed has a different chromosomal complement than all the others in the 
embryo a misdiagnosis occurs [31]. 
 
Misdiagnosis can be considered to be either adverse or benign. Adverse 
misdiagnoses are those that result in a severe adverse event for the patient 
(including the birth of an affected child or termination of an affected pregnancy in 
cases where the embryo transferred was thought to be unaffected). In the case of 
benign misdiagnoses, examples include the birth of an unaffected child carrying a 
mutation when the transferred embryo was thought to be free of the tested 
mutation. Alternatively, misdiagnosis may be identified after confirmatory testing on 
untransferred embryos a procedure that should be performed at least periodically 
as a quality assurance measure [32].  
 
The European Society of Human Reproduction and Embryology (ESHRE) 
PGD Consortium has collected data on PGD cycles and deliveries since 1997 
(Table 2.1). A low misdiagnosis rate has been observed 24/15,158 (0.16%), 
although the rate for PCR-based cycles 12/2538 (0.5%) is relatively higher than 










No. of misdiagnosis 
reported to consortium 
Total number of 
cycles to PGD/PGS 
% Misdiagnosis 
Sexing for X-linked disease FISH 2 803 0.25 
Sexing for X-linked disease PCR 2 65 3.08 
Translocations FISH 3 2514 0.12 
PGS FISH 6 8822 0.07 
Social sexing FISH 1 481 0.21 




24 15 158 0.16 
 
 
 General causes of misdiagnosis 
There are a number of possible causes of misdiagnosis (Table 2.2). Some 
causes are specific to the technology or test methodology involved (i.e. PCR or 
FISH based tests), but many apply equally to both PCR and FISH. An example is 
cumulus cell contamination that can affect both FISH (by inadvertently providing an 
additional „female‟ nucleus) and PCR (by inadvertently providing both maternal 
alleles) diagnoses. In either case, it is vital that all cumulus cells are removed prior 
to biopsy. The other causes of misdiagnosis include confusion of embryo and cell 
number, transfer of the wrong embryo, maternal or paternal contamination, ADO, 
use of incorrect and inappropriate probes or primers, probe or primer failure and 
chromosomal mosaicism. Unprotected sex has been mentioned as a cause of 
adverse outcome not related to technical and human errors. The majority of these 
causes can be prevented by using robust diagnostic methods within laboratories 
working to appropriate quality standards. However, diagnosis from a single cell 
remains a technically challenging procedure, and the risk of misdiagnosis cannot 




Table 2.2. Summary of the causes of misdiagnosis in PGD [32] 
 
Factor Error type PCR FISH Examples of preventative action 
Unprotected sex Human √ √ Written instructions for patients to avoid unprotected sex 
during treatment. Use of oral contraceptive pill 
Mislabeled tube or 
slide 
Human √ √ Comprehensive, robust labeling system and SOP 
Misidentified tube, slide 
or embryo 
Human √ √ Appropriate witnessing procedures 
Misinterpreted report Human √ √ Appropriate training, report and counseling 
Transfer of wrong 
embryo 
Human √ √ Appropriate training, report, witnessing and counseling 
Use of incorrect probes 
or primers 












Removal of second cell. Use of informative-linked STR/SNP. 
Test polar bodies. Develop test to determine origin of 
aneuploidy (PCR only) 
Probe or primer failure 
Extrinsic 
(technical) 
√ √ Adequate pre-clinical validation. Use WGA to allow repeat 




























Remove more than 1 cell at biopsy. Include up to three 




Human √ √ Ensure validation is overseen by experienced/ licensed 





Removal of more than 1 cell at biopsy. Include up to three 




Due to the chance of misdiagnosis as well as the presence of aneuploidies, 





2.3. Single cell lysis and DNA extraction methods 
Tsuchiya et al. (2005) have recently developed a new DNA extraction 
method, called the „„Spanning  protocol.‟‟ These investigators reported that their 
spanning protocol decreases the incidence of amplification failure, as well as the 
rate of false-negatives. Therefore, their laboratory assessed the rate of 
amplification and the occurrence of ADO using general DNA extraction methods as 
well as the spanning protocol using single lymphocytes as a PCR template. They 
compared various lysis buffers: lysis in distilled water with freezing and thawing 
using liquid nitrogen, lysis in distilled water, alkaline lysis buffer, Proteinase 
K/Sodium Dodecyl Sulfate (SDS) buffer, and N-lauroylsarcosine salt solution. 
Amplification rates ranged from 84.8% to 97.5%. The efficiency of the DNA  
amplification from single lymphocytes was 89.0% (138 of 155) following lysis in 
distilled water using the freeze–thaw lysis method, 88.1% (133 of 151) with the 
distilled water method, 97.5% (153 of 157) with the alkaline lysis buffer method, 
91.5% (129 of 141) with the Proteinase K/SDS buffer method, and 84.8% (123 of 
145) with the N-lauroylsarcosine salt solution method [29] .  
 
When Kim et al. compared the accuracy of five DNA extraction methods, the 
alkaline lysis method was the most efficient method for extracting DNA from a 
single cell with lowest rates of ADO and should be particularly useful for PGD [29]. 
2.4. Whole genomic amplification (WGA) 
WGA is a technique that can specifically increase the DNA quantities 
originating from samples with limited DNA contents. Application of WGA would 
greatly enhance maneuverability when starting with genetic material  derived from 
just a single cell. Earlier approaches of WGA included  the use of primers for 
repeated interspersed sequences. Several other methods have been later 
developed to amplify the whole genome by using random or partly degenerate 
primers. Recently, a new isothermal WGA method was introduced by using 
bacteriophage phi29 DNA polymerase and random hexamer primers [33].  
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2.4.1. Principal methods for WGA: 
    2.4.1.1. Primer Extension Preamplification (PEP) 
PEP was first used for the haplotyping of a single sperm cell. PEP involves 
PCR cycling and the use of Taq polymerase and a 15-base random oligonucleotide 
primer (Figure 2.7). However, unlike the standard PCR, following denaturation, the 
primers are allowed to anneal to the DNA genomic template at a low temperature 
(37 ◦C), and then they are slowly heated to 55 ◦C followed by a 4 min elongation 
step at 55 ◦C. This PCR-based WGA method has been used to develop PGD 
protocols for the single-cell analysis of sex-linked sequences, Tay-Sachs disease, 
cystic fibrosis, Duchenne muscular dystrophy deletions, the detection of mutations 
causing ß-thalassemia, and familial adenomatous polyposis coli mutations. PEP 
was also successfully used on DNA from ethanol fixed paraffin embedded tissues 
and formalin fixed paraffin embedded tissues. The PEP method has been modified 
and Improved PEP (IPEP) since its inception. IPEP-PCR has been shown to have 
an increased efficiency of amplification compared to PEP-PCR by using restriction 
fragment length polymorphism analysis of single cells. However, a PEP and IPEP 
have number of disadvantages, including the limited amplification yield and 
imbalanced amplification of highly polymorphic microsatellite repeat linked makers, 
especially the common dinucleotide repeats. These pitfalls have discouraged the 















2.4.1.2. Degenerate Oligonucleotide Primed PCR  (DOP-PCR) 
DOP-PCR was first described by Telenius et al. (1992) as a method for 
genome mapping studies. DOP, like PEP, is a well established and widely 
accepted WGA method. The technique has been used for single nucleotide 
polymorphism (SNP) genotyping, microsatellite genotyping CGH to identify 
aneuploidies in a single cell, and mutation detection by single stranded 
conformational polymorphism (Figure 2.8). DOP has been widely used for a 
substantially low quantity of starting DNA template, maximization of amplification 
yield, and wider coverage. Technically, this method uses a partially DOP that is 
capable of annealing at low temperatures to many sites (~106) in the genome 
during the preamplification cycles. This is followed by PCR amplification at higher 
temperatures to allow specific fragment amplification. DOP has advantages and 
limitations. For example, good representation was demonstrated when genetic 
analysis of DOP amplified DNA was compared to non amplified DNA of the same 
specimens. Grant et al. (2002), on the other hand, reported ambiguous SNP calls 
for DOP amplified DNA, which was attributed to poor quality of the DNA template. 
ADO was reported when <1 ng of genomic DNA (~150 cells) was amplified, and 
the contrary was also reported. Finally, DNA from fresh and fixed tissue has been 
successfully amplified by DOP-PCR and subsequently used for genetic analysis.  
PEP and DOP are both PCR-dependent, and they rely on symmetrical placement 
of adapters at the ends of each of the genomic DNA fragments to be amplified. 
This presents a risk of bias and uneven distribution of these adaptors on each and 
every fragment to be amplified. This is further complicated by the introduction of 
artificial sequence variations into the amplification products via the degenerate 
PCR primers that are used. It is therefore not unusual to expect significant ADO 
and biased amplification of the whole genome when these methods are used, 
specially when scarce amounts of DNA are available or when the DNA template is 
degraded or partially degraded. This is very critical when the source of the starting 
genetic material is just a single cell (e.g. a blastomere) and the ADO happens to 















Figure 2.8 Degenerate Oligonucleotide Primed PCR [34]. 
 
2.4.1.3. Multiple Displacement Amplification (MDA) 
The third method for WGA is isothermal, and does not require thermal 
cycling to amplify the genomic material. This method, unlike PEP and DOP, 
depends on MDA using bacteriophage phi29 DNA  polymerase and random 
hexamer primers (Figure 2.9). MDA has several advantages, such as its high 
processivity of phi29 DNA polymerase that generates fragment sizes of >10 kb. 
The enzyme also has better proofreading activity that results in lower 
misincorporation rates compared to Taq DNA polymerase that is used by the other 
WGA methods. Studies have shown that phi29 has an error rate of 1 in 106–107 
compared to the 3 in 10 000 error rate for the native Taq DNA polymerase  or 1.6 
in 106 for phi29. MDA can be performed by using either Bst or phi29 DNA 
polymerases. Phi29 DNA polymerase is preferred over Bst DNA polymerase since 
the latter showed lower efficiency and a high error rate compared to phi29. After 
the introduction of MDA as a new principal method for WGA, two commercially 
available kits have been introduced (GenomePhi DNA amplification kit, GE 
Healthcare and REPLI-g kit, Qiagen Inc.). Both kits have been successfully used in 
single-cell and PGD applications. MDA depends on the use of random hexamer 
primers that are thiophosphate-modified at their 3 end to protect them from 
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degradation by the 3`→ 5` exonuclease proofreading activity of phi29 DNA 
polymerase. On the basis of the features described above, MDA has been broadly 
applied on different clinical samples and it has allowed a high-throughput 
genotyping without the need for intermediate and laborious DNA extraction 
procedures. Genome coverage in the amplified DNA, as assessed by multiple SNP 
analysis, is equivalent to genomic DNA when amplifying from as little as 0.3 ng of 
template DNA (~ 45 cells equivalent) and the amplification bias is superior to the 
PEP and DOP methods of WGA. Moreover, MDA products have been preferred 
over DOP-PCR products for array CGH applications. A major limitation to MDA is 
its intolerance to amplification from unusual sources of template DNA, such as 
DNA derived from fixed paraffin tissues or degraded DNA. Short and/or cross-
linked DNA are not ideal for the MDA method. It is predicted that MDA will 
generate, from such samples, amplification products that are insufficient in 
























2.4.2. problems of whole genome amplification 
 
2.4.2.1. Preferential amplification and allele dropout 
 
Both preferential amplification (PA) and ADO are the potential problems that 
can cause misdiagnosis, and they seem to be mainly generated during the WGA  
reaction The PA rates in MDA could range from 6.9% to 60.7%, while the ADO 
rates in MDA could reach 10.0%–38.9%, which are comparable to those obtained 
by direct amplification of single cell loci (20%–40%). The following factors can 
account for PA. First of all, differential denaturation because of the GC percentage 
differences between alleles was one important factor that could lead to PA. 
Moreover, the short allele product can be amplified preferentially, even when the 
target DNA has been sufficiently degraded. In addition, PA is closely associated to 
the initial number of genomes sampled. When it is very small, it can easily cause 
PA. Along with the factors mentioned above, less efficient priming of DNA 
synthesis of one allele is another factor that can result in PA of the other allele, 
because of mismatches between the primer and the specific allelic template. As to 
ADO, it depends on the cell type analyzed, the genes tested, and the lysis 
conditions, as well as the PCR conditions. For autosomal recessive conditions 
when both partners are carrying the same mutation, ADO will not cause serious 
misdiagnosis, but the number of embryos available for transfer would decrease 
and this may result in a poor pregnancy rate. For compound heterozygous or 
autosomal dominant conditions, the results are quite contrary to those autosomal 
recessive conditions, and the consequences of ADO could be catastrophic for 
transferring affected embryo: longer alleles, that is, with a larger number of 
repeats, either paternal or maternal. Frumkin et al. (2008) found that longer alleles 
had significantly higher dropout rates  when compared with their corresponding 
shorter alleles. The small quantity of the WGA products that used in the following 




2.4.2.2. Slippage of microsatellites 
Microsatellites are short segments of DNA that have a repeated sequence, 
such as STRs or simple tandem repeats. The slippage of microsatellites is very 
common in PCR-based WGA methods, such as PEP and DOP-PCR. The 
amplification of repetitive DNA sequences, such as STRs, increased or decreased 
by a number of base pairs equivalent to one repeat length, presumably caused by 
slippage of the DNA chain during product generation, is probably due to the low 
annealing temperatures which are characteristic of PCR-WGA protocols. 
Moreover, the research using quantitative fluorescence multiplex PCR has shown 
that PA obviously exists in microsatellite heterozygote, and ADO occurs frequently 
as well. For these reasons, PCR-based WGA methods are infrequently used in 
aneuploidy diagnosis. However, the slippage of microsatellites does not seem to 
occur among the MDA products. Consequently, a misdiagnosis due to a 
discrepancy with genomic DNA could be substantially reduced by MDA, improving 
the outcome of PGD [2]. 
2.5. Sex Selection 
Sex selection is the practice of using medical techniques to choose the sex 
of one‟s offspring. Sex-selection procedures can also be divided into two technical 
(and temporal) categories: (1) prenatal procedures; and (2) preimplantation 
procedures. Prenatal procedures are those that take place after conception and 
after implantation of the embryo in a woman‟s uterus. Preimplantation procedures 
take place even before the sperm or embryo is introduced into the woman‟s body 
[36]. 
Additionally, Sex-selection procedures can be practiced for two different 
reasons: (1) procedures done for medical reasons; and (2) procedures done for 
non-medical, elective reasons. While there is some debate among physicians, 
ethicists, and the general public about the level of medical necessity that should 
justify a sex selection procedure, most accept that sex selection for medical 
reasons is beyond ethical reproach, and in some situations, should even be 
encouraged. However, elective, non-medical sex-selection, which is often 
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performed for social or financial reasons, is the subject of greater scrutiny and 
impassioned ethical debate. Non-medical sex selection procedures, on the other 
hand, are undergone for a variety of reasons, but few are as clear-cut as those 
cited for medical sex selection [36]. 
There are three core motivations for engaging in sex determination and sex 
selection: 
 medical reasons such as preventing the birth of children affected or at risk of 
X-linked disorders. 
 family balancing reasons where couples choose to have a child of one sex 
because they already have one or more children of the other sex. 
 gender preference reasons often in favour of male offspring stemming from 
cultural, social, and economic bias in favour of male children and as a result 
of policies requiring couples to limit reproduction to one child, as in China 
[37] .  
Human female and male differ in that there are two X chromosomes in 
normal female and both an X and Y chromosome in normal male. Each of the 
gametes, i.e. eggs in women and sperm in men, provide a sex chromosome for the 
developing embryo at the time of fertilization. All of the sex chromosomes in eggs 
are X chromosomes. The sperm contain either an X or a Y chromosome. 
Therefore, the sex of the offspring is determined by male‟s contribution to the 
embryo [38]. 
 
The differences between X and Y spermatozoa (X and Y haploid cells) may 
exist in two areas: the different chromosomes (i.e. different kinds and numbers of 
genes) and the different sperm structures and functions (i.e. different genetic 
expression). The existence of X and Y spermatozoa was first proposed in the 
1920s. Since then, several methods have been utilized for the sex determination in 
spermatozoa. The finished sequences of both human sex chromosomes have now 




2.5.1. Sex-Determining Region on Y chromosome (SRY) 
The SRY gene, which is located in the Yp11.3 region of Y chromosome and 
encodes a transcription factor that is a member of the high mobility group (HMG)-
box family of DNA binding proteins. It is a testis-specific transcription factor that 
plays key role in sexual differentiation and development in males. SRY is an 
intronless gene that spans 3.8 kb, with an open reading frame encoding a 204 
amino acids protein with an estimated molecular mass of 24 kDa. Mutation in the 








Figure 2.10 Human Y chromosome in cytogenetic view. Focus on SRY gene [41]. 
 
 Cui et. al. (1997) used primers that were selected from the conserved motif 
of the SRY and the control primers from the human ZP3 gene (on chromosome 7). 
Blood DNA extracted from 57 men and 67 women accurately confirmed the correct 
origins of the substrate DNA and, therefore, the primer selection. The SRY primers 
also showed high specificity to human rather than other animals. SRY and ZP3 
genes were confirmed to be present in 9 of 10 single lymphocytes of male origin 
while 9 out of 10 female-derived single lymphocytes contained only the ZP3 gene 
with the double lysis method. The remaining two lymphocytes (one male and one 
female) did not amplify. In a previous study, 58 male and female lymphocytes 
showed 100% PCR amplification and correct diagnosis with the lymphocyte lysis 




2.5.2. Glucose-6-phosphate dehydrogenase (G6PD) 
G6PD is a cytosolic enzyme which its main function is to produce NADPH in 
the red blood cells by controlling the step from Glucose-6-Phosphate to 6-Phospho  
gluconate in the pentose phosphate pathway. G6PD deficiency is the most          
common X-chromosome linked hereditary enzymopathy in the world, that result in 
reduced enzyme activity and more than 125 different mutations causing it have 
been identified. The G6PD gene is located in the Xq28 region of X chromosome. It 
contains 13 exons and 12 introns and is 18.5 kb in length, encodes a protein of 515 
amino acids. It is highly polymorphic and more than 400 different variants have 











Figure 2.11 Human X chromosome in cytogenetic view. Focus on G6PD [45]. 
 
Vandervorst et al. (2000) have published 5 years experience of PGD for the 
diagnosis of severe inherited disorders. From October 1993 to October 1998, 183 
PGD cycles were done in 92 couples. PCR was used for specific diagnosis and 
FISH for sexing (n=64). The result of 24 (of 29) PGD were confirmed by prenatal 
diagnosis or after birth. One pregnancy was terminated after misdiagnosis. As a 
result of one misdiagnosis, replacement of embryos now only occurs if the results 
of two blastomeres are identical. The implantation rate was 12% and the 





The Farah Hospital in Amann - Jordan has the most extensive experience in 
performing PGD for family balancing and family size. They have been performing 
this technique for several years and implantation rates are above the normal range. 
Out of 66 children born from PGD, all had the desired gender and were normal at 1 
year follow up. In addition to its use in sex selection, sex chromosome aneuploidy 
is detected by FISH-PGD [6]. 
 
2.5.1. Sex selection of embryos for non-medical reasons 
In some countries PGD is currently used for gender selection even in the 
absence of medical reasons. For example, Israeli parents who have at least four 
children of the same sex and want one of the other sex can now apply to a health 
ministry committee for approval of PGD at their own expense. Officials issued the 
directive on basis of the recommendation of experts on bioethics and they would 
approve sex selection of embryos for social reasons only in very unusual cases. 
Except for one case officially approved by the ministry, all procedures done at 
Israeli hospitals for PGD have, until now, involved a family history indicating a high 
risk of serious genetic disorders. Such disorders include Tay-Sachs disease and 
familial dysautonomia (both of which occur mostly in Jews), as well as  
thalassaemia, myotonic dystrophy, neurofibromatosis, fragile X syndrome, 
haemophilia, and Marfan‟s syndrome. Now the committee, which comprises 
experts in law, medical genetics, and obstetrics, a social worker, and a clergyman, 
will decide whether a couple or single woman can choose, for social reasons, the 
desired sex among the resultant embryos through IVF and PGD. Israel‟s policies 
on IVF are among the world‟s most liberal, with fertility units in every general 
hospital and with the health funds covering the cost of producing two babies for 







Materials and Methods 
 
3.1. Study population   
The study sample consisted of 30 human embryos (45 blastomeres) 
obtained after 7 ICSI cycles.  Embryos used  in this study were surplus embryos 
following embryo transfer. 
3.2. Ethical Considerations  
Informed consent was obtained from all embryo donors and the researcher 
explained the objective of the study to them. 
3.3. Materials 
 
3.3.1. Chemicals and Reagents 
 
Chemicals and reagents used in this study are shown in Table 3.1. All 
chemicals were of analytical and molecular biology grade. 
 
 Table 3.1. Chemicals and reagents used in the present study. 
Reagent  Supplier 
REPLI-g Mini Kit (25) Qiagen, USA 
PCR Master Mix Promega, Madison, WI, USA 
Agarose Promega, Madison, WI, USA 
Nuclease free water Promega, Madison, WI, USA 
DNA molecular size marker (ladder),100bp Promega, Madison, WI, USA 
PCR primers Promega, Madison, WI, USA 
Ethidium Bromide (Et.Br) 10mg/ml Promega, Madison, WI, USA 
PCR loading Solution (Bromophenol Blue) 
0.25% Bromophenol blue 40% (w/v) sucrose in water 
Promega, Madison, WI, USA 
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Acidified Tyrode‟s solution Global, USA 
 
3.3.2. Disposables 
The major disposables used in this study are listed in Table 3.2. 
  














3.3.3. Equipments  
     All experiments of this study were done at the Genetics Laboratory of Islamic 
University of Gaza and Embryology laboratory of Banoon and Qurat Aun IVF 
Center. The major equipment that were used are listed in Table 3.3. 
 
Table 3.3. Major equipments used in the present study. 
Item Supplier 
Blastomere Biopsy Pipette Cook®, Australia 
Holding Pipette Cook®, Australia 
Pasteur Pipettes Sigma, USA 
Tissue culture dish (small, large) Falcon, germani  
Microcentrifuge Tubes, 1.5 ml Capacity Labcon, USA 
Microcentrifuge Tubes, 0.2 ml Capacity Labcon, USA 
PCR pipette tips Labcon, USA 
Disposables Gloves Free Powder Weihai Sun Genius - China 
Instrument  Manufacturer 
Thermocycler Eppendorf, Germany 
Electrophoresis chambers/tanks BioRad, USA 
Electrophoresis power supply BioRad, USA 















3.3.4. PCR Oligonucleotide Primers 
Nucleotide sequence of PCR primers (indicated from 5′-3′) employed in this 
study are shown in Table 3.3. Sense primers end with F (for forward), while 
antisense end with R (for reverse) [44,46]. 
 









3.4. Methods  
3.4.1. Blastomeres Processing   
 
 One or two cells were removed through a hole made in the zona pellucida, 
from each of 30 human embryos at the 4-8 cell cleavage stage three days after 
ICSI. By using an inverted microscope and a micromanipulator, the zona pellucida 
Pipettes  Gilson, France 
Vortex Mixer LW Scientific – USA 
Instrument  Manufacturer 
Nanophotometer  Imblen GmbH, Munich, Germany. 
Gel Documentation System Vision, SCIE-Plas Ltd, UK  
Safety Cabinet Heraeus, Germany 
Inverted Microscopes Olympus, Japan 
Micromanipulator  Narishige, Japan 











583 69 C 
G6PD-R GAAGAGTAGCCCTCGAGGGTGACT 







was opened by using a blastomere pipette (35-49 μm dimeter) containing acid 
Tyrode's solution (pH 2.4) (Figure 3.1). During processing the embryo was 
immobilized by a holding pipette and a blastomere with a visible nucleus was 
removed by gentle suction. Under a stereomicroscope each single or double 
blastomeres from each embryo were then separated by mouth pipetting using a 
fine glass pipette (pulled on flame to approximately the size of a blastomeres), 
washed in Phosphate Buffered Saline (PBS) and transferred into 0.2 ml eppendorf 






Figure 3.1. Blastomere biopsy procedure. (a) embryo at 4-cells stage is encased with the zp. (b) 
embryo with a hole in zp after acid Tyrods. (c) blastomere biopsy micropipette is inserted through 
zp. (d) a single blastomere is extracted from the embryo by suction; (e) biopsied blastomere with a 
clearly visible single nucleus (indicated by arrow) [47]. 
 
• Note: To verify that blastomere biopsy is a harmless process, the embryos 
were incubated in a special medium and where monitored for development, it was 
noted 10 of 30 (33 %) embryos biopsied on day 3 post-insemination developed to 
blastocysts, 8 (26 %) developed to morula, 3 (10 %) degenerates and 9 (30 %)  
Continued to grow and then stop at different stage (8, 10, 12 cells).  
 
3.4.2. Blastomere genomic DNA isolation and amplification 
 
Blastomeres were lysed and genomic DNA was amplified by using REPLI-g 
Mini Kits (Qiagen, Valencia, CA, USA) adhering to the manufacturer protocol, 
which can be summarized as follows: 
1. Nuclease-free water (500 μl) were  added to Buffer DLB, mixed well and    
centrifuged briefly. 
2. REPLI-g Mini DNA Polymerase was thawed on ice. 
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3. Sufficient Buffer D2 was prepared for the total number of amplification reactions 
(See table 3.5). 
 








4. PBS (2.5 μl)  was mixed with 0.5 μl cell material in a microcentrifuge tube. 
5. Buffer D2 (3.5 μl) was added. Mixed by vortexing and centrifuged briefly. 
6. The samples were incubated on ice for 10 minutes. 
7. Stop Solution (3.5 μl) was added. Mixed by vortexing and centrifuged briefly. 
8.  Master mix was prepared on ice as shown in (Table 3.6), mixed and centrifuged 
briefly.  









9. Master mix (40 μl) was added to 10 μl denatured DNA obtained from    
blastomeres (steps above). 
10. The mixture was incubated at 30°C for 10 –16 hours. 
11. REPLI-g Mini DNA Polymerase was inactivated by heating samples for 3  
minutes at 65°C. 
Component Volume 
Reconstituted Buffer BLD 55 μl 
Dithiothreitol (DTT), 1M  5  μl 
Total volume 60 μl 
Component Volume per reaction 
Nuclease-free water 10   μl 
REPLI-g Mini Reaction Buffure 29   μl 
REPLI-g Mini DNA polymerase   1    μl 
Total volume 40   μl 
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12. The quality of the amplified DNA was monitored on ethidium bromide stained 
1% agarose gels and the quantity of DNA was measured by a 
spectrophotometer at  260 nm. 
11. Finally, the DNA was stored at 2-8˚C until PCR analysis is carried out. 
3.4.3. Molecular analysis 
 
3.4.3.1. SRY gene specific PCR 
 
    PCR was carried out in a monoplex fashion for each primer set. For SRY, PCR 
was carried out in 0.2 ml PCR microfuge tubes in a 20 µl reaction volume 
containing: 2 µl template genomic DNA (100-200 ng), 10 µl PCR Master mix, 2 µl   
(2.7 µmol) of each primer, and nuclease free sterile distilled water to 20 µl. The 
amplification reaction was performed in a programmable thermal cycler. 
Amplification was started with an initial denaturation step at 94˚C for 15 minutes, 
followed by 35 sequential cycles each including 1 minute denaturation at 94˚C, 1 
minute primer annealing at 57˚C and 1 minute extension at 72˚C. The protocol was 
followed by a final extension step at 72˚C for 10 minutes and then cooling to 4˚C to 
be ready for electophoretic detection. 
 
3.4.3.2. G6PD gene specific PCR 
 For G6PD, PCR was carried out in 0.2 ml PCR microfuge tubes in a 20 µl 
reaction volume containing: 2 µl template genomic DNA (100-200 ng), 10 µl PCR 
Master mix, 2 µl ( 2.7 µmol) of each primer, and nuclease free sterile distilled water 
to 20 µl. The amplification reaction was performed in a programmable thermal 
cycler. Amplification was started with an initial denaturation step at 96˚C for 10 
minutes, followed by 30 sequential cycles each including 1 minute denaturation at 
94˚C, 90 seconds primer annealing at 61˚C and 3 minute extension at 72˚C. The 
protocol was followed by a final extension step at 72˚C for 10 minutes and then 
cooling to 4˚C to be ready for electophoretic detection. 
 
3.4.3.3. Controls 
Positive and negative controls were run concurrently with each sample 
batch. In blastomere genomic DNA amplification, the positive control consisted of 
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EDTA blood sample. Cell-free fluid wash was used as a blank to check for false 
positive results.  
In PCR reaction, male and female genomic DNA extracted by Genomic DNA 
extraction Kit (Promega, Madison, WI, USA) was used as a positive control to 
check for any PCR failure. 
In PCR negative control the DNA in the reaction mixture was replaced by 
nuclease free water. The negative control is used to check for contamination. 
 
 
3.4.3.5. Electrophoresis detection 
 The PCR product was added to 2.5 µl loading dye, mixed and run on a 1 % 
(w/v) agarose gel containing 0.5 µg/ml Et.Br in 1x Tris Acetate EDTA (TAE) buffer, 
pH 8.0. In addition, a 100 bp DNA ladder was always run concurrently to detect 
product size. After electrophoresis at 70 volts for 45 minutes, the results were 
visualized and documented using an UV transilluminator documentation system 





  Results 
4.1. Whole genomic DNA amplification 
In this study, DNA isolated from the 45 blastomers (obtained from the 30 
embryos) successfully amplified and therefore was included for sex determination 
analysis.  
 
The DNA quantity was measured by a nanophotometer after amplification. 
The DNA concentration ranged from 200 to 600 ng (Table 4.1). 
 









Assuming that a single blastomere contains an average of ~ 6 ng/µl [48], the 
amplification level thus ranged from ~ 30 to 100 fold.  











Figure 4.1. Ethidium bromide stained 1% agarose gel for whole human genomic  DNA extracted 
and amplified from blastomeres. M: 100 bp DNA ladder, Lane1: single cell blastomere, Lane 2: 
positive control (peripheral blood genomic DNA), Lane 3: two blastomere, Lane 4: negative control. 
Genomic DNA is evident near the gel wells.  
No. of balastomere 
Amplified DNA 
concentration (ng/ µl) 
Single blastomere 460-470 
Double blastomere 400-580 
Three blastomere 230-280 















Of the 30 embryos, 7 (23 %) were found to be male where the PCR 
amplicon resulted from the amplification of SRY gene with a size of (472) bp. The 
remaining embryos 23, (77 %) were of female gender as only the G6PD amplicon 












Figure 4.2. Ethidium bromide stained agarose gel for SRY gene. M: 100 bp DNA ladder, Lane1: 
positive control, Lane 2: SRY amplicon (472 bp) and G6PD amplicon (583 bp) obtained from WGA-
PCR of  a single blastomere , Lane 3:negative control. Note: for the sake of illustration, SRY and G6PD 













Figure 4.3. Ethidium bromide stained agarose gel for G6PD gene. M: 100 bp DNA ladder, Lane1: 
positive control, Lane 2: G6PD amplicon (583 bp) obtained from single cell WGA-PCR of  a single 











































The present study investigated the feasibility of isolating blastomeres, whole 
genomic amplification and locus specific PCR for the first time in Gaza strip. 
 
In most IVF centers, perforation of the ZP is performed by using acid 
Tyrode‟s, and only a few centers are employing diode laser biopsy. Acid Tyrode‟s 
has been used most often because many IVF centers are reluctant to switch to the 
simpler and faster laser drilling because of paucity of studies comparing outcomes 
of both methods after PGD. For instance in  the study of Jonis et al. showed that 
blastocysts development rates (and blastocyst quality) were similarly high in both 
the acid Tyrode‟s - and in the laser - drilled ZP indicating that laser hatching is not 
necessary for blastomere biopsy.[49, 50].  
 
The obtained results indicate that WGA using the REPLI-g Mini Kit is 
sensitive to very low amounts of DNA, down to the single genome level and no 
amplification signals were detected in blank samples. Genomic DNA amplification 
was obtained from all samples illustrating the high efficiency of this kit. 
 
The WGA for genetic analysis in PGD is encouraging and the clinical uses 
of this technique is on the rise. Currently, clinical applications of WGA provide very 
promising amplification efficiency. WGA opens the door for multiple tasks which 
need abundant DNA. MDA-based genome amplification has been recognized as 
the most effective WGA at present, and has become one of the main techniques in  
PGD. As compared with other PCR-based WGA methods (e.g., PEP and DOP), 
MDA generates DNA with a higher molecular weight (as evident in Figure 4.1) and 
shows better genome coverage. MDA employs φ29 DNA polymerase which has 
the advantages of high processivity, 3`- 5` proof-reading activity and strand 
displacement capability. The whole procedure takes 3 hours and generates 
appreciable amounts of DNA from single blastomeres (Table 4.1), which is suitable 
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for multiple downstream applications, such as locus-specific PCR, sequencing, 
STR analysis or array-CGH [33, 51]. 
 
The genome coverage of MDA from single cells has not yet been 
conclusively determined; however, array-CGH carried out by Spits et al. on MDA-
amplified DNA from single cells revealed that all genome regions tested were 
amenable to MDA [51]. 
 
One major problem of current PGD procedures is the limited time available 
for diagnosis while retaining embryo viability. Usually embryos are biopsied early 
on day 3 post-insemination. The time needed for PCR-based genetic analysis 
using REPLI-g Mini Kit is capable of giving a result within 24 hours (i,e., day 4 post-
insemination). During this period embryos can be cultured in blastocyst media. This 
strategy would allow the embryo biopsy to be performed at a time more dependent 
on embryo development and allow for the transfer the embryos without 
cryopreservation. 
Another problem that may be encountered in PGD is the occurrence of 
mosaicism. Mosaicism occurs when some blastomeres of an embryo have different 
genetic complement. Thus the blastomere biopsied for PGD may not represent the 
rest of the embryo and could result in an adverse outcome. Trophoblast biopsies 
remove several cells which can be compared. Mosaicism can therefore be 
detected and accounted for.  
 
 
Gender selection is an issue that has been raised by the new technological 
advances in science. Parents can pick and choose the sex of their children based 
on their needs. In some countries, economic and social conditions have resulted in 
the use of sex selection being biased towards male children. Economic and social 
pressures may encourage couples to have male children who can inherit family 
land and provide for extended families. Whilst sex selection for medical reasons 
(e.g. sex-linked diseases) the choice is toward female gender and appears 
generally to be about the health and well-being of the prospective child, non-




In this context we have used a PCR assay for the simultaneous detection of 
loci on X and Y chromosomes in human blastomeres. Both X- and Y-specific 
fragments were amplified with primers which are common to both chromosomes 
and are derived from the SRY and the G6PD genes. Both an X and a Y fragments 
amplify in male embryos and due to the absence of a Y chromosome, only X 
fragment amplifies in females. The efficiency and accuracy of this assay are high; it 
generates no false positive amplification signals and allows sexing in 4 hours after 
WGA. We therefore believe that the whole procedure presented in this work is 
suitable for gender determination by PGD for couples at risk for sex-linked genetic 
diseases and for non–medical sex selection. Moreover, the obtained DNA should 
be amenable to other molecular analyses such as array CGH and SNP analysis, 
and may enable the detection of a wider spectrum of specific inherited disorders 
[7].  
 
PGD tests have largely relied focused on two methodologies: FISH and 
PCR. FISH has largely superseded PCR. Application of PCR protocols to single 
cell analyses has proved to be challenging but ultimately highly successful, and 
remains the only means of detecting specific mutations in PGD. On the other hand, 
PCR assay is quick, simple and ideally suited for single cell diagnosis, the products 
being easily visualized on an agarose gel [52, 53]. 
 
Liu et al. have proved that the PCR assay for the simultaneous detection of 
fragments from both the X and the Y chromosomes in single human blastomeres is 
fast since a result can be obtained in 6 hours after blastomere biopsy [7]. 
 
In contrast to the FISH methodology, a PCR assay such as the one 
described here will not detect fetuses with aberrant numbers of X or Y 
chromosomes. For instance, klinefelter syndrome (XXY), turner syndrome (XO) 
and 46,XX true hermaphrodite embryos will be diagnosed as being male and 
female, respectively. Additionally, FISH is less prone to contamination and can also 
provide the copy number for each chromosome tested but cannot serve as a 
screening test for all chromosomes in a single cell because most FISH techniques 
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can only detect limited numbers of chromosomes and may fail to detect single 
gene disorders and microdeletions smaller than 190 kb [54].  
 
In conclusion, this study describes, for the first time in Gaza strip, a WGA-
PCR assay for the simultaneous detection of fragments from both the X and the Y 
chromosomes from single human blastomeres. The assay is relatively fast and the 
efficiency and accuracy from this assay are high, such that it could be used for 










 WGA using the REPLI-g Mini Kit is efficient and sensitive to very low 
amounts of DNA present in single blastomeres and efficient in yielding high 
molecular weight genomic DNA. 
 
 
 Locus-specific PCR proved to be an easy and successful technique for 
embryo sex determination and is expected to be suitable for detection of 
various gene mutations.   
6.2. Recommendations 
 
 We recommend the IVF centers in Gaza Strip to start applying PGD in order 
to help specific groups of patients with high rates of chromosome 
abnormalities and single gene disorders. 
 
 The introduction of array-based diagnostic techniques such as CGH 
because it evaluates all chromosomes from a single cell. 
 
 Laws should be enacted in order to regulate the process of non-medical sex 
selection of embryos in Gaza Strip. 
 
 Research on trophectoderm biopsy is encourage and recommended as an 
alternative to blastomere biopsy. Trophectoderm biopsy would provide more 
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